USE OF RHEOGLUMAN IN ACUTE MYOCARDIAL-INFARCTION

The efficacy of rheogluman was evaluated in 55 patients with acute myocardial infarction. ECG mapping recordings in 35 leads showed that an earlier positive dynamics in SIGMA-ST, SIGMA-Q, and SIGMA-R was significantly observed in patients treated with rheogluman than in untreated patients. These data indirectly indicated a reduction in the periinfarct zone in the acute period of myocardial infarction. The serum concentrations of lysosomal enzymes (creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, alanine amino-transferase) became normal earlier in the rheogluman-treated patients than in the controls. This fact may be regarded as a protective effect of the drug on the formation of a necrotic focus.